TITAN (Treatment In Thoracic Aortic aNeurysm) is a network of over 30 aortic centers collaboratively tackling important questions in the management of thoracic aortic disease. We aim to discover new insights and execute practice-defining clinical trials that will shape future society guidelines and clinical practice. 

Thoracic aortic disease ranks among the top 20 causes of death in North America, despite being an uncommon disease. The vast majority of guideline recommendations for the management of thoracic aortic disease are based on lower-quality evidence from non-randomized, often single-center, retrospective studies. Only 1-2% of current guideline recommendations are based on randomized, controlled trials.

The Treatment In Thoracic Aortic aNeurysm (TITAN) clinical trials accelerator was initiated with the launch of its flagship trial, TITAN:SvS, funded by the Canadian Institutes for Health Research. The network has now grown to over 30 sites across North America and is conducting 4 trials in aortic disease. 

The TITAN network is supported by the University of Ottawa Heart Institute Cardiovascular Research Methods Center (UOHI-CRMC), the Calgary Image Processing and Analysis Center (CIPAC), which serves as the imaging core lab, and the University of Ottawa Heart Institute Biobank. 

TITAN aims to elevate the level of evidence, enable new discoveries, and facilitate integration of new technologies in the management of thoracic aortic disease.